X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TT-10, an oral small molecule drug targeting the Adenosine A2A receptor (A2AR) in patients with advanced solid tumors both as a monotherapy and in combination with other anti-cancer agents.
Lead Product(s): TT-10
Therapeutic Area: Oncology Product Name: TT-10
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Portage Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
As a result of the transaction, Portage acquires four best-in-class assets including TT-10/PORT-6, targeting different aspects of the adenosine pathway, and is now in a unique position to evaluate the role of adenosine in cancer and other diseases.
Lead Product(s): PORT-6
Therapeutic Area: Oncology Product Name: TT-10
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Portage Biotech
Deal Size: $53.0 million Upfront Cash: $21.0 million
Deal Type: Acquisition July 06, 2022
Details:
TT-4, an oral small molecule drug targeting the Adenosine A2B receptor (A2BR). Tarus plans to initiate a Phase 1a/1b study in the third quarter of 2021 to evaluate TT-4 in patients with advanced solid tumors both as a monotherapy and in combination.
Lead Product(s): TT-4
Therapeutic Area: Oncology Product Name: TT-4
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2021
Details:
The application includes extensive preclinical data on TT-4's biological activity and safety profile, as well as details on how the therapy would be manufactured and administered to trial participants.
Lead Product(s): TT-4
Therapeutic Area: Oncology Product Name: TT-4
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2021
Details:
The application includes extensive preclinical data on TT-10's biological activity and safety profile, as well as details on how the therapy would be manufactured and administered to trial participants.
Lead Product(s): TT-10
Therapeutic Area: Oncology Product Name: TT-10
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
